Published in J Pharmacol Exp Ther on April 07, 2006
Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int (2012) 1.82
Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol (2008) 1.35
Recent progress in the treatment of vascular calcification. Kidney Int (2010) 1.18
Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J Pharmacol (2009) 1.13
Increased expression of host iron-binding proteins precedes iron accumulation and calcification of primary lung lesions in experimental tuberculosis in the guinea pig. Tuberculosis (Edinb) (2007) 1.08
The dualistic role of vitamin D in vascular calcifications. Kidney Int (2010) 0.98
Can vitamin D slow down the progression of chronic kidney disease? Pediatr Nephrol (2011) 0.90
Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol (2009) 0.89
Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities. Front Immunol (2015) 0.84
Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Des (2014) 0.83
Relation of oral 1alpha-hydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients. Heart Vessels (2010) 0.81
Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol. J Cell Biochem (2010) 0.81
Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol (2009) 0.80
Active vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study. Am J Hypertens (2014) 0.78
Pre-treatment considerations in childhood hypertension due to chronic kidney disease. World J Nephrol (2015) 0.75
Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism. Calcif Tissue Int (2017) 0.75
Superior recovery profiles of propofol-based regimen as compared to isoflurane-based regimen in patients undergoing craniotomy for primary brain tumor excision: a retrospective study. J Anesth (2012) 2.01
Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol (2005) 1.78
Vitamin D receptor (VDR) localization in human promyelocytic leukemia cells. Leuk Lymphoma (2006) 1.49
Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis (2005) 1.49
A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol (2003) 1.17
Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol (2007) 1.04
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. PLoS One (2012) 1.02
Reduced heart size and increased myocardial fuel substrate oxidation in ACC2 mutant mice. Am J Physiol Heart Circ Physiol (2008) 0.98
Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A (2004) 0.96
Systemic activation of the calcium sensing receptor produces acute effects on vascular tone and circulatory function in uremic and normal rats: focus on central versus peripheral control of vascular tone and blood pressure by cinacalcet. J Pharmacol Exp Ther (2007) 0.95
Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res (2006) 0.94
Blood pressure regulation by ETA and ETB receptors in conscious, telemetry-instrumented mice and role of ETA in hypertension produced by selective ETB blockade. Am J Physiol Heart Circ Physiol (2006) 0.94
Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res (2003) 0.93
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev (2004) 0.93
VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J Cell Biochem (2007) 0.92
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem (2004) 0.92
Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol (2007) 0.91
Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J Med Chem (2005) 0.91
Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thromb Res (2005) 0.90
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety. J Med Chem (2006) 0.89
A nonsteroidal glucocorticoid receptor antagonist. Mol Endocrinol (2003) 0.88
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem (2006) 0.88
Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells. Am J Physiol Renal Physiol (2007) 0.87
Differential effects of Vitamin D analogs on calcium transport. J Steroid Biochem Mol Biol (2006) 0.86
Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol (2004) 0.86
Computer-assisted imaging algorithms facilitate histomorphometric quantification of kidney damage in rodent renal failure models. J Pathol Inform (2012) 0.86
High glucose induced oxidative stress and apoptosis in cardiac microvascular endothelial cells are regulated by FoxO3a. PLoS One (2013) 0.85
A-350619: a novel activator of soluble guanylyl cyclase. Life Sci (2003) 0.85
Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5). Biochem Pharmacol (2004) 0.84
Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant (2008) 0.84
Delivery of RNAi reagents in murine models of obesity and diabetes. J RNAi Gene Silencing (2006) 0.83
Amplified inflammatory response to sequential hemorrhage, resuscitation, and pulmonary fat embolism: an animal study. J Bone Joint Surg Am (2010) 0.82
ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Anticancer Drugs (2009) 0.82
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction. J Med Chem (2006) 0.81
Mechanistic analysis of VDR-mediated renin suppression. Nephron Physiol (2007) 0.81
Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors. J Pharmacol Exp Ther (2011) 0.81
Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav (2005) 0.81
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. J Med Chem (2006) 0.81
Synthesis and functional activity of (2-aryl-1-piperazinyl)-N-(3-methylphenyl)acetamides: selective dopamine D4 receptor agonists. Bioorg Med Chem (2004) 0.80
Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway. Metabolism (2009) 0.80
Vitamin d receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats. Int J Endocrinol (2010) 0.80
Two novel vitamin D receptor modulators with similar structures exhibit different hypercalcemic effects in 5/6 nephrectomized uremic rats. Am J Nephrol (2013) 0.80
Extrapancreatic roles of glimepiride on osteoblasts from rat manibular bone in vitro: Regulation of cytodifferentiation through PI3-kinases/Akt signalling pathway. Arch Oral Biol (2010) 0.79
Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats. Life Sci (2012) 0.79
Strategic integration of in vivo cardiovascular models during lead optimization: predictive value of 4 models independent of species, route of administration, and influence of anesthesia. J Cardiovasc Pharmacol (2012) 0.79
VS-105: a novel vitamin D receptor modulator with cardiovascular protective effects. Br J Pharmacol (2011) 0.79
Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors. J Pharmacol Toxicol Methods (2011) 0.79
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis (2015) 0.79
Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Int J Endocrinol (2010) 0.79
Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists. J Med Chem (2005) 0.78
Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem (2004) 0.78
TH1 and TH2 cytokine inhibition by 3,5-bis(trifluoromethyl)pyrazoles, a novel class of immunomodulators. Cell Immunol (2002) 0.78
ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor. J Pharmacol Exp Ther (2004) 0.78
Effects of BW245C, a prostaglandin dp receptor agonist, on systemic and regional haemodynamics in the anaesthetized rat. Clin Exp Pharmacol Physiol (2005) 0.78
Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs? Curr Opin Investig Drugs (2005) 0.78
Differential effects of Vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol (2005) 0.78
Tumour-selective antivascular effects of the novel anti-mitotic compound A-318315: An in vivo rat regional haemodynamic study. Clin Exp Pharmacol Physiol (2010) 0.78
Differential effects of vitamin d receptor agonists on gene expression in neonatal rat cardiomyocytes. Cardiovasc Drugs Ther (2011) 0.77
Synthesis and evaluation of 3-aryl piperidine analogs as potent and efficacious dopamine D4 receptor agonists. Bioorg Med Chem (2005) 0.77
Histamine in cardiac sympathetic ganglia: a novel neurotransmitter? Mol Interv (2006) 0.77
A prospective cohort study of ALI/ARDS in the Tohoku district of Japan (second report). J Anesth (2010) 0.77
A preliminary study of platelet activation after embolization of marrow contents. J Orthop Trauma (2012) 0.77
Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5/6 nephrectomized rats. Physiol Rep (2013) 0.76
Cardiovascular disease in chronic kidney failure: the role of VDR activators. Curr Opin Investig Drugs (2006) 0.76
Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorg Med Chem Lett (2004) 0.75
Low-dose but not high-dose prostaglandin E(1) improves the histological outcome of severe forebrain ischemia in rats. J Anesth (2010) 0.75
[Expression of RASAL2 in hepatocellular carcinoma and the clinical significance]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2015) 0.75
[Severe asthmatic crisis during general anesthesia in a patient with IgG4 related disease]. Masui (2014) 0.75
[Cranial subdural hematoma with intracranial hypotension related to epidural anesthesia and Trendelenburg position: a case report]. Masui (2011) 0.75
Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents. Clin Exp Pharmacol Physiol (2005) 0.75
Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogs. J Cardiovasc Pharmacol (2005) 0.75
[Clinical effect of TACE combined with radiofrequency ablation in treatment of malignant tumor at the second porta hepatis]. Zhonghua Gan Zang Bing Za Zhi (2016) 0.75
[Correlation between the expression of C-terminal tensin-like protein and the prognosis of hepatocellular carcinoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2014) 0.75
[Anesthetic management of two cases with placenta percreta that caused massive hemorrhage during cesarean section]. Masui (2008) 0.75
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine. J Cardiovasc Pharmacol (2004) 0.75
[Effect of glimepiride on the glucose uptake of rat mandibular osteoblasts in hyperglycemia]. Hua Xi Kou Qiang Yi Xue Za Zhi (2014) 0.75
Synthesis and activity of 2-[4-(4-[3H]-2-cyanophenyl)piperazinyl]-N-(2,4,6-[3H]3-3-methylphenyl)acetamide: a selective dopamine D4 receptor agonist and radioligand. Bioorg Med Chem Lett (2004) 0.75